Current and emerging treatment options for hairy cell leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Hairy cell leukemia (HCL) is a B-cell lymphoproliferative disorder with characteristic clinical features.
• Accurate diagnosis is crucial to distinguish classic HCL from treatment-resistant variants.
• Current standard therapy involves purine analogs (PAs), achieving high remission rates but with significant relapse rates (~30%-40%).

Purpose of the Study:

• To review the current landscape of HCL treatment.
• To highlight the need for novel therapeutic targets and agents for HCL.
• To discuss ongoing research and clinical trials exploring new treatment strategies.

Main Methods:

• Review of current literature on HCL diagnosis and treatment.
• Analysis of standard-of-care therapies, including purine analogs and rituximab.
• Examination of emerging therapeutic targets and ongoing clinical trials.

Main Results:

• Purine analogs (PAs) are effective but associated with patient relapse.
• Combination therapy with PAs and rituximab improves response rates.
• Discovery of the BRAF mutation has opened avenues for targeted therapies.

Conclusions:

• Despite effective treatments, HCL management requires further improvement due to relapses and refractory cases.
• Novel therapeutic strategies, including BRAF inhibitors and B-cell receptor signal inhibitors, are under investigation.
• Future research aims to identify agents for a universal cure for HCL.